Annie Wong-Beringer

List of Publications by Year
in descending order

68 papers	3,797 citations	172207 29 h-index	128067 60 g-index
69 all docs	69 docs citations	69 times ranked	3999 citing authors

#	Article	IF	Citations
1	High-Dose Vancomycin Therapy for Methicillin-Resistant Staphylococcus aureus Infections. Archives of Internal Medicine, 2006, 166, 2138.	4.3	777
2	Therapeutic monitoring of vancomycin for serious methicillin-resistantStaphylococcus aureusinfections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. American Journal of Health-System Pharmacy, 2020, 77, 835-864.	0.5	640
3	Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. International Journal of Antimicrobial Agents, 2011, 37, 95-101.	1.1	162
4	Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. International Journal of Antimicrobial Agents, 2008, 32, 378-385.	1.1	158
5	Regulatory Oversight and Safety of Probiotic Use. Emerging Infectious Diseases, 2010, 16, 1661-1665.	2.0	154
6	Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clinical Infectious Diseases, 2020, 71, 1361-1364.	2.9	142
7	Molecular Correlation for the Treatment Outcomes in Bloodstream Infections Caused byEscherichia coliandKlebsiella pneumoniaewith Reduced Susceptibility to Ceftazidime. Clinical Infectious Diseases, 2002, 34, 135-146.	2.9	131
8	Use of an Efflux Pump Inhibitor To Determine the Prevalence of Efflux Pump-Mediated Fluoroquinolone Resistance and Multidrug Resistance in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2005, 49, 565-570.	1.4	129
9	Applying New Diagnostic Criteria for Acute Kidney Injury To Facilitate Early Identification of Nephrotoxicity in Vancomycin-Treated Patients. Antimicrobial Agents and Chemotherapy, 2011, 55, 3278-3283.	1.4	83
10	Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes. Clinical Infectious Diseases, 2020, 70, 566-573.	2.9	82
11	Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes. Journal of Antimicrobial Chemotherapy, 2005, 55, 535-541.	1.3	72
12	Comparison of type III secretion system virulence among fluoroquinolone-susceptible and -resistant clinical isolates of Pseudomonas aeruginosa. Clinical Microbiology and Infection, 2008, 14, 330-336.	2.8	67
13	Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	66
14	Differentiation in Quinolone Resistance by Virulence Genotype in Pseudomonas aeruginosa. PLoS ONE, 2012, 7, e42973.	1.1	60
15	Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation. Clinical Therapeutics, 2016, 38, 16-30.	1.1	60
16	A Dysregulated Balance of Proinflammatory and Anti-Inflammatory Host Cytokine Response Early During Therapy Predicts Persistence and Mortality in Staphylococcus aureus Bacteremia*. Critical Care Medicine, 2016, 44, 671-679.	0.4	55
17	Systemic Antifungal Therapy: New Options, New Challenges. Pharmacotherapy, 2003, 23, 1441-1462.	1.2	50
18	Economic Aspects of Antibacterial Adverse Effects. Pharmacoeconomics, 1998, 13, 35-49.	1.7	49

#	Article	IF	Citations
19	A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. Journal of Antimicrobial Chemotherapy, 2010, 65, 1765-1770.	1.3	49
20	Wavelength-normalized spectroscopic analysis of Staphylococcus aureus and Pseudomonas aeruginosa growth rates. Biomedical Optics Express, 2016, 7, 4034.	1.5	48
21	An Antimicrobial Stewardship Program with a Focus on Reducing Fluoroquinolone Overuse. Pharmacotherapy, 2009, 29, 736-743.	1.2	46
22	Fitness Cost of Fluoroquinolone Resistance in Clinical Isolates of Pseudomonas aeruginosa Differs by Type III Secretion Genotype. Frontiers in Microbiology, 2016, 7, 1591.	1.5	45
23	Absolute Bioavailability and Pharmacokinetics of Linezolid in Hospitalized Patients Given Enteral Feedings. Antimicrobial Agents and Chemotherapy, 2005, 49, 3676-3681.	1.4	44
24	Safety and efficacy of Intralipid emulsions of amphotericin B. Journal of Antimicrobial Chemotherapy, 1996, 38, 333-347.	1.3	39
25	In Vitro Activity of Daptomycin in Combination with Î²-Lactams, Gentamicin, Rifampin, and Tigecycline against Daptomycin-Nonsusceptible Enterococci. Antimicrobial Agents and Chemotherapy, 2015, 59, 4279-4288.	1.4	39
26	Risk factors for early return visits to the emergency department in patients with urinary tract infection. American Journal of Emergency Medicine, 2018, 36, 12-17.	0.7	35
27	Influence of timing of antibiotic administration on tissue concentrations during surgery. American Journal of Surgery, 1995, 169, 379-381.	0.9	33
28	Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 281-284.	0.6	33
29	Implementing a program for switching from i.v. to oral antimicrobial therapy. American Journal of Health-System Pharmacy, 2001, 58, 1146-1149.	0.5	29
30	Risk of Developing Pneumonia Is Enhanced by the Combined Traits of Fluoroquinolone Resistance and Type III Secretion Virulence in Respiratory Isolates of Pseudomonas aeruginosa*. Critical Care Medicine, 2014, 42, 48-56.	0.4	29
31	Implementation of rapid diagnostics with antimicrobial stewardship. Expert Review of Anti-Infective Therapy, 2016, 14, 1065-1075.	2.0	28
32	Suitability of Caspofungin for Aerosol Delivery. Chest, 2005, 128, 3711-3716.	0.4	27
33	Emergency Department Urinary Antibiograms Differ by Specific Patient Group. Journal of Clinical Microbiology, 2017, 55, 2629-2636.	1.8	27
34	Microbicidal effects of Î±- and Î¸-defensins against antibiotic-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Innate Immunity, 2015, 21, 17-29.	1.1	25
35	Performance of Ceftolozane-Tazobactam Etest, MIC Test Strips, and Disk Diffusion Compared to Reference Broth Microdilution for Î²-Lactam-Resistant Pseudomonas aeruginosa Isolates. Journal of Clinical Microbiology, 2018, 56, .	1.8	23
36	Improving the completeness of public metadata accompanying omics studies. Genome Biology, 2021, 22, 106.	3.8	22

#	Article	IF	Citations
37	Rhesus Î¸-defensin-1 (RTD-1) exhibitsin vitroandin vivoactivity against cystic fibrosis strains ofPseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2016, 71, 181-188.	1.3	21
38	Leveraging Antimicrobial Stewardship in the Emergency Department to Improve the Quality of Urinary Tract Infection Management and Outcomes. Open Forum Infectious Diseases, 2018, 5, ofy101.	0.4	21
39	Patients presenting to the hospital with MRSA pneumonia: differentiating characteristics and outcomes with empiric treatment. BMC Infectious Diseases, 2014, 14, 252.	1.3	20
40	Impact of carbapenem resistance on epidemiology and outcomes of nonbacteremic Klebsiella pneumoniae infections. American Journal of Infection Control, 2015, 43, 1076-1080.	1.1	18
41	Impact of Socioeconomic Status and Race on Sepsis Epidemiology and Outcomes. Journal of applied laboratory medicine, The, 2021, 6, 194-209.	0.6	16
42	Reducing empirical use of fluoroquinolones for Pseudomonas aeruginosa infections improves outcome. Journal of Antimicrobial Chemotherapy, 2008, 61, 714-720.	1.3	14
43	Antivirulence Potential of TR-700 and Clindamycin on Clinical Isolates of Staphylococcus aureus Producing Phenol-Soluble Modulins. Antimicrobial Agents and Chemotherapy, 2011, 55, 4432-4435.	1.4	13
44	Utility of qSOFA score in identifying patients at risk for poor outcome in Staphylococcus aureus bacteremia. BMC Infectious Diseases, 2019, 19, 149.	1.3	12
45	Applying patient selection criteria for drotrecogin alfa therapy in practice. American Journal of Health-System Pharmacy, 2003, 60, 1345-1345.	0.5	11
46	Pneumococcal Vaccination in Hospitalized Elderly Patients: Role of the Pharmacist. Pharmacotherapy, 2003, 23, 199-208.	1.2	10
47	Early Response Assessment to Guide Management of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections With Vancomycin Therapy. Clinical Therapeutics, 2013, 35, 995-1004.	1.1	10
48	Tigecycline Induction of Phenol-Soluble Modulins by Invasive Methicillin-Resistant Staphylococcus aureus Strains. Antimicrobial Agents and Chemotherapy, 2013, 57, 4562-4565.	1.4	10
49	Prevalence of the carbapenem-heteroresistant phenotype among ESBL-producing Escherichia coli and Klebsiella pneumoniae clinical isolates. Journal of Antimicrobial Chemotherapy, 2020, 75, 1506-1512.	1.3	9
50	Cytokine measurements add value to clinical variables in predicting outcomes for Staphylococcus aureus bacteremia. BMC Infectious Diseases, 2021, 21, 317.	1.3	7
51	Differential effects of antibiotics on neutrophils exposed to lipoteichoic acid derived from Staphylococcus aureus. Annals of Clinical Microbiology and Antimicrobials, 2020, 19, 50.	1.7	6
52	Can clinical and molecular epidemiologic parameters guide empiric treatment with vancomycin for methicillin-resistant Staphylococcus aureus infections?. Diagnostic Microbiology and Infectious Disease, 2011, 70, 124-130.	0.8	5
53	Antibiotics Differentially Modulate Lipoteichoic Acid-Mediated Host Immune Response. Antibiotics, 2020, 9, 573.	1.5	5
54	Factors associated with prompt recovery among hospitalised patients with coronavirus disease 2019. International Journal of Clinical Practice, 2021, 75, e14818.	0.8	5

#	Article	IF	Citations
55	Increased Risk of Thrombocytopenia and Death in Patients with Bacteremia Caused by High Alpha Toxin-Producing Methicillin-Resistant Staphylococcus aureus. Toxins, 2021, 13, 726.	1.5	5
56	Treating Serious Infections: Focus on Cefepime. Pharmacotherapy, 2004, 24, 216S-223S.	1.2	4
57	The use of oligonucleotide recombination to generate isogenic mutants of clinical isolates of Pseudomonas aeruginosa. Journal of Microbiological Methods, 2014, 98, 23-25.	0.7	4
58	Predictive Performance of a Vancomycinâ€“Aminoglycoside Population Model. Annals of Pharmacotherapy, 1998, 32, 176-181.	0.9	3
59	Staphylococcus aureus Bacteremia in Patients not Meeting Sepsis Criteria: Clinical Features, Host Immune Response and Outcomes. , 2017, 2, .		3
60	In-Human Multiyear Evolution of Carbapenem-Resistant Klebsiella pneumoniae Causing Chronic Colonization and Intermittent Urinary Tract Infections: A Case Study. MSphere, 2022, 7, e0019022.	1.3	2
61	Criteria for use of amphotericin B lipid complex injections in adults and children. American Journal of Health-System Pharmacy, 1996, 53, 2751-2752.	0.5	1
62	Nebulizer Choice Affects the Airway Targeting of Amphotericin B Lipid Complex Aerosols. Journal of Pharmacy Technology, 2013, 29, 199-204.	0.5	1
63	Questions on Vancomycin Dosing. Clinical Infectious Diseases, 2020, 73, e1777-e1778.	2.9	1
64	Risk factors and outcome associated with infection or colonization due to carbapenem-heteroresistant Escherichia coli. JAC-Antimicrobial Resistance, 2021, 3, dlab036.	0.9	1
65	Variable Release of Lipoteichoic Acid From Staphylococcus aureus Bloodstream Isolates Relates to Distinct Clinical Phenotypes, Strain Background, and Antibiotic Exposure. Frontiers in Microbiology, 2020, 11, 609280.	1.5	1
66	Persistent Bacillus cereus Bacteremia in an Immunocompetent Host. Infectious Diseases in Clinical Practice, 2004, 12, 294-296.	0.1	0
67	Differences in Clinical Presentation and Outcome Between Extended-Spectrum Beta-Lactamase (ESBL) Versus Non-ESBL Urinary Tract Infections (UTIs) in a Medically Underserved Population. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
68	Clinically significant bacteria/pyuria-the author responds. American Journal of Emergency Medicine, 2017, 35, 1561.	0.7	0